Debbie Shawcross

Q: What Schools Are Affiliated With Debbie Shawcross

Debbie Shawcross is affiliated with the following schools: Imperial College London, University of Oxford, King's College London

Debbie Shawcross's AcademicInfluence.com Rankings

Debbie Shawcross

Philosophy

#10943

World Rank

#15019

Historical Rank

Logic

#7777

World Rank

#9646

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Debbie Shawcross Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Debbie Lindsay Shawcross is a British physician and clinician who is a professor at King's College London. Her research looks to better understand the cellular and molecular mechanisms that underpin chronic liver disease, with a focus on the gut-liver-brain axis.

(See a Problem?)

Debbie Shawcross's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. (2004) (463)
High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. (2016) (380)
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease (2019) (365)
Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement (2011) (291)
Role of ammonia and inflammation in minimal hepatic encephalopathy (2007) (222)
Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. (2011) (217)
The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation (2005) (217)
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. (2003) (209)
Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. (2015) (197)
Endotoxemia produces coma and brain swelling in bile duct ligated rats (2007) (194)
Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis (2010) (174)
CD14, CD16 and HLA‐DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA‐DR expression by CD14hi/CD16neg monocytes: Expansion of CD14hi/CD16pos and contraction of CD14lo/CD16pos monocytes in acute liver failure (2012) (162)
Meld score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation (2007) (150)
Ammonia impairs neutrophil phagocytic function in liver disease (2008) (147)
The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120). (2020) (146)
Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. (2015) (145)
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease (2018) (133)
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. (2018) (121)
Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. (2010) (114)
Inflammation and hepatic encephalopathy. (2013) (113)
Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension (2007) (113)
Dispelling myths in the treatment of hepatic encephalopathy (2005) (107)
Pathophysiology of cerebral oedema in acute liver failure. (2013) (107)
Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis (2020) (106)
Systemic inflammation and ammonia in hepatic encephalopathy (2013) (101)
Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy (2004) (99)
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. (2020) (98)
Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure-Sequential Organ Failure Scoring System. (2015) (93)
Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease (2017) (91)
The molecular pathogenesis of hepatic encephalopathy. (2003) (91)
Neutrophil gelatinase—Associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation (2010) (86)
Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. (2004) (80)
Circulating neutrophil dysfunction in acute liver failure (2013) (76)
Balanced haemostasis with both hypo‐ and hyper‐coagulable features in critically ill patients with acute‐on‐chronic‐liver failure (2018) (74)
Targeting the gut-liver-immune axis to treat cirrhosis (2020) (68)
Ammonia and Hepatic Encephalopathy: The More Things Change, the More They Remain the Same (2005) (65)
The neurological manifestations of acute liver failure (2012) (64)
The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90‐day and 1‐year mortality (2014) (64)
Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis (2017) (64)
The impact of organ dysfunction in cirrhosis: survival at a cost? (2012) (64)
Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis (2016) (60)
The microbiota in cirrhosis and its role in hepatic decompensation. (2021) (54)
Cerebral oedema is rare in acute‐on‐chronic liver failure patients presenting with high‐grade hepatic encephalopathy (2014) (52)
The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin‐α (2016) (50)
The 6-month abstinence rule in liver transplantation (2010) (49)
Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase (2016) (48)
Intestinal Virome in Patients With Alcoholic Hepatitis (2020) (47)
Recent insights into the pathogenesis of hepatic encephalopathy and treatments (2014) (44)
Character and Temporal Evolution of Apoptosis in Acetaminophen-Induced Acute Liver Failure* (2013) (40)
Regulation, risk and safety of Faecal Microbiota Transplant (2020) (33)
In vitro efficacy of pro‐ and anticoagulant strategies in compensated and acutely ill patients with cirrhosis (2018) (33)
Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. (2021) (33)
Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all‐cause admissions in patients on the liver transplant waiting list (2019) (32)
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. (2022) (32)
Alcohol dehydrogenase–specific T‐cell responses are associated with alcohol consumption in patients with alcohol‐related cirrhosis (2013) (32)
Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. (2020) (32)
How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist (2015) (31)
Comparison of scoring systems and outcome of patients admitted to a liver intensive care unit of a tertiary referral centre with severe variceal bleeding (2014) (28)
Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? (2015) (27)
Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. (2020) (26)
PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial (2019) (25)
Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease (2019) (24)
Subacute liver failure secondary to black cohosh leading to liver transplantation (2013) (22)
The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS) (2017) (21)
Pathophysiological mechanisms of hepatic encephalopathy (2015) (20)
Outcome of patients with cirrhosis admitted to intensive care (2008) (20)
Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure (2016) (20)
Clinical science workshop: targeting the gut-liver-brain axis (2016) (20)
Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. (2022) (19)
Diagnosis and management of hepatic encephalopathy. (2018) (19)
Gut-derived systemic inflammation as a driver of depression in chronic liver disease. (2021) (19)
Is treating the gut microbiome the key to achieving better outcomes in cirrhosis? (2018) (18)
Treatment of hepatic encephalopathy: It's not lactulose (2004) (16)
Platelet‐leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion (2018) (15)
Polymorphisms in ABCB11 and ATP8B1 Associated with Development of Severe Intrahepatic Cholestasis in Hodgkin's Lymphoma. (2013) (14)
Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity (2021) (13)
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease (2022) (12)
Clinical and cytokine response to anti-TNF antibody therapy in severe alcoholic hepatitis. (2001) (11)
Severe alcohol-related liver disease admissions post-COVID-19 lockdown: canary in the coal mine? (2020) (11)
Dysfunctional neutrophil effector organelle mobilization and microbicidal protein release in alcohol-related cirrhosis. (2017) (11)
Salivary microbiota‐immune profiling in cirrhosis: Could this be the noninvasive strategy that will revolutionize prognostication in hepatology? (2015) (10)
Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. (2001) (10)
Ammonia-Induced Brain Edema Requires Macrophage and T Cell Expression of Toll-Like Receptor 9 (2019) (9)
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH) (2022) (6)
The Reactobiome Unravels a New Paradigm in Human Gut Microbiome Metabolism (2021) (6)
Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase (2015) (6)
E/A ratio alone cannot reliably diagnose diastolic dysfunction in the assessment before and after TIPS. (2007) (5)
Global and temporal state of the human gut microbiome in health and disease (2021) (5)
Should a biopsy precede liver resection or transplantation for presumed hepatocellular carcinoma when the alfa fetoprotein is normal? (2004) (5)
Neutrophil CD64 expression is elevated in acetaminophen-induced acute liver failure. (2012) (5)
The quest for the elusive factors that underpin neutrophil dysfunction in cirrhosis goes on. (2012) (5)
Could abnormal neutrophil‐platelet interactions and complex formation contribute to oxidative stress and organ failure in cirrhosis? (2015) (5)
Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients with Alcoholic Hepatitis. (2021) (5)
Old versus new antiepileptic drugs: the SANAD study (2007) (4)
Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis (2021) (4)
Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis (2020) (4)
Lamotrigine and the risk of fulminant hepatic failure (2008) (4)
OC-029 Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience (2014) (4)
Reversal of acquired hepatocerebral degeneration with living donor liver transplantation (2016) (4)
Acute liver failure and the brain: a look through the crystal ball (2013) (4)
Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial (2020) (4)
faecal microbiota transplantation reduces pathogenic burden and is anti-inflammatory in patients with advanced cirrhosis (2020) (3)
Lessons Learned from Faecal Microbiota Transplantation in Cirrhosis (2020) (3)
928 EX VIVO TREATMENT OF NEUTROPHILS WITH A P38 MAPK AGONIST IN PATIENTS WITH ACUTE AND CHRONIC LIVER FAILURE AND ELEVATED ARTERIAL AMMONIA IMPROVES BACTERIOCIDAL CAPACITY (2011) (3)
Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver Transplantation (2021) (3)
A dent in our sobriety (2009) (3)
Editorial: rifaximin—a kick in the gut for spontaneous bacterial peritonitis? (2018) (3)
Systemic inflammation and ammonia in hepatic encephalopathy (2012) (3)
175 UTILITY OF ORGAN FAILURE PROGNOSTIC SCORING SYSTEMS IN A LARGE COHORT OF CRITICALLY ILL PATIENTS WITH CIRRHOSIS: IMPROVED PREDICTION OF IN-HOSPITAL MORTALITY OVER MELD (2011) (3)
Management of multidrug-resistant infections in cirrhosis. (2022) (2)
Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation? (2021) (2)
O034 : Frequency and function of anti-bacterial mait cells are significantly impaired in advanced alcoholic liver disease (2015) (2)
The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis (2021) (2)
Neutrophil vacuolation in acetaminophen‐induced acute liver failure (2015) (2)
245 NEUTROPHIL INTRACELLULAR TOLL-LIKE RECEPTOR (TLR) 9 EXPRESSION SERVES AS A BIOMARKER THAT DETERMINES PRESENCE AND SEVERITY OF ENCEPHALOPATHY IN ACUTE LIVER FAILURE AND CIRRHOSIS (2012) (2)
System biology prediction model based on clinical data: highly accurate outcome prediction in patients with acute-on-chronic liver failure (2012) (2)
540 A COMPENSATORY ANTI-INFLAMMATORY RESPONSE SYNDROME (CARS) TRIGGERED BY NEUTROPHIL-INDUCED OXIDATIVE STRESS IS ASSOCIATED WITH CHRONIC LOW GRADE HEPATIC ENCEPHALOPATHY IN PATIENTS WITH ADVANCED CIRRHOSIS (2010) (2)
Management of problems in liver diseaseHepatic encephalopathy (2015) (2)
Acute-on-Chrenic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction (2009) (2)
Baseline neutrophil to lymphocyte ratio can identify favourable corticosteroid response in alcoholic hepatitis (2017) (2)
Changing outcomes in patients with chronic liver disease in intensive care: a decade of experience (2012) (2)
787 Worsening of cerebral hyperemia in acute liver failure with severe hepatic encephalopathy following terlipressin (2003) (2)
Multivariate metabotyping of plasma accurately predicts survival in patients with decompensated cirrhosis * (2017) (2)
P: 12 PROFIT: PROspective, Randomised Placebo-controlled Feasibility Trial of Faecal Microbiota Transplantation in Cirrhosis Interim Analysis (2019) (2)
Exaggerated inflammatory response to bacterial products in decompensated cirrhotic patients is orchestrated by interferons IL-6 and IL-8 (2022) (1)
DEFINING THE OUTCOME, PRECIPITANTS AND COST OF SEVERE HEPATIC ENCEPHALOPATHY (HE) IN CIRRHOSIS (2008) (1)
The rise and fall and rise again of ammonia as a therapeutic target in HE (2022) (1)
Response to "MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation". (2008) (1)
Pathophysiology: Gut Liver Axis Changes (2018) (1)
Increased apoptotic activity is associated with hospital mortality and disruption in lipid homeostasis in acute-on-chronic liver failure. (2013) (1)
246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis (2019) (1)
629 CEREBRAL OEDEMA IS RARE IN ACUTE-ON-CHRONIC LIVER FAILURE (AOCLF) (2012) (1)
OC-021 Monocyte oxidative burst defect is associated with susceptibility to infection in severe alcoholic hepatitis (2015) (1)
Diarrhoea and preadmission antibiotic exposure in COVID-19: a retrospective cohort study of 1153 hospitalised patients (2021) (1)
Low myo-inositol and high glutamine levels in the brain are associated with neuropsychological deterioration following induced hyperammonemia (2004) (1)
Treatment of hepatic encephalopathy. Authors' reply (2005) (1)
P1329 : A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy (‘RIFSYS’) (2015) (1)
Systemic inflammation determines ammonia-induced neuropsychological deterioration in cirrhosis. (2004) (1)
The changing face of hepatic encephalopathy: A projection for the next 5 years (2016) (1)
Statins: A Panacea to Reduce Mortality in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma? (2021) (1)
Meeting the challenge of antimicrobial resistance in cirrhosis: the invisible threat that lies within. (2021) (1)
PWE-088 Frequency and function of anti-bacterial mait cells are significantly impaired in advanced alcoholic liver disease (2015) (1)
Decompensation of chronic stable alcoholic liver disease by severe exfoliative dermatitis. (2003) (0)
[213] LIPOPOLYSACCHARIDE EXACERBATES BRAIN EDEMA AND PRODUCES COMA IN CIRRHOTIC RATS THROUGH A CYTOTOXIC MECHANISM: AN ELECTRON-MICROSCOPIC STUDY (2007) (0)
Dramatic Alterations of Anti-Bacterial Mait-Cell Network in Alcoholic Liver Disease (2016) (0)
Alpha1-antitrypsin deficiency. (2009) (0)
SUSCEPTIBILITY TO INFECTION IN PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS (2013) (0)
588 The Impact on Hospital Resource Utilization of Rifaximin-α for Hepatic Encephalopathy in Routine Clinical Practice: Real World Data From Seven UK Liver Centres (2015) (0)
The Formation of Activated Platelet-Complexed Leukocytes is Augmented in Cirrhosis and Enhanced by Platelet Transfusion (2016) (0)
P312 UNTARGETED H-NMR SPECTROSCOPY DEMONSTRATES A UNIQUE METABOLIC PHENOTYPE OF ALCOHOLIC HEPATITIS (2014) (0)
541 SUSCEPTIBILITY TO INFECTION IN PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS: A NOVEL ROLE FOR PD-1 AND GALECTIN-9? (2013) (0)
MAIT cell dysfunctions correlate with markers of intestinal integrity in ALD patients (2017) (0)
Effect of prednisolone therapy on monocyte phenotype and function in alcoholic hepatitis (2016) (0)
PTU-046 Metabolic profiling of plasma by NMR spectroscopy accurately predicts outcome in patients with decompensated cirrhosis and acute on chronic liver failure (2012) (0)
Rifaximin reduces the incidence of sepsis and all cause admissions whilst on the liver transplant waiting list (2018) (0)
Inflammation significantly exacerbates the effect of hyperammonemia on neurological function in cirrhosis (2003) (0)
targeting of gut bacterium attenuates alcoholic liver disease. (2019) (0)
Reduced Neutrophil Function Persists 72 Hours Following Liver Transplantation Despite Normalization of Arterial Ammonia (2010) (0)
Let's Have Some Clarity on Academic Parity. (2022) (0)
P40 Ex vivo treatment of neutrophils with a p38-MAPK agonist in patients with liver failure improves their bacteriocidal capacity (2010) (0)
Plasma angiopoietin 2 as a novel prognostic biomarker in alcohol-related cirrhosis and hepatitis (2022) (0)
Prophylactic rifaximin use in liver transplant candidates is associated with false positive results of the alcohol biomarker, ethyl sulphate (2020) (0)
Protocol: A prospective, randomised placebo-controlled feasibility trial of Faecal microbiota Transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO) (2020) (0)
Reply to 'Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients'. (2022) (0)
P314 CHARACTERISATION OF THE PLASMA METABOLIC PHENOTYPE OF ACUTE LIVER FAILURE BY H NMR SPECTROSCOPY (2014) (0)
Ammonia Mediated Brain-oedema and Immune Dysfunction is Mediated by Toll-like Receptor (TLR) 9 (2016) (0)
An 18-year-old girl with retrosternal burning discomfort: a bitter pill to swallow (2021) (0)
The gut microbiota in hepatic encephalopathy (2021) (0)
Foreword. (2020) (0)
PREDICTING THE OUTCOME OF SEVERE VARICEAL GASTROINTESTINAL BLEEDING (2010) (0)
OP32 Modernising Hepatology training: An international comparison of the current and new 2022 UK Hepatology curriculum (2022) (0)
P054 Long term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long term follow-up (IMPRESS II) (2021) (0)
Hyperammonaemia is an independent biomarker of liver-related complications and mortality in clinically stable outpatients with cirrhosis (2022) (0)
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease (2019) (0)
Should a biopsy precede liver resection or transplantation for presumed HCC when the AFP is normal (2004) (0)
article : the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease (2017) (0)
Reply to 'The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?' (2022) (0)
Dysfunctional Mucosa-associated invariant T-cells link intestinal immunity with susceptibility to bacterial infection in Alcoholic Liver Disease (2017) (0)
FRI-116-Capturing the complexities of the immune system in patients with advanced cirrhosis using a whole blood culture system reveals a robust inflammatory response to endotoxin stimulation (2019) (0)
1002 INCREASED ACTIN PRODUCTION IN NEUTROPHILS IN ACUTE AND CHRONIC LIVER FAILURE REPRESENTS ADAPTATION TO FACILITATE CHEMOTAXIS, PHAGOCYTOSIS AND CYTOKINESIS (2013) (0)
Moderate hypothermia abolishes neutrophil oxidative burst induced by hyperammonemia but phagocytosis is unaffected (2005) (0)
THU-418 - Ammonia-Induced Brain Oedema and Immune Dysfunction is Mediated by Toll-Like Receptor 9 (TLR9) (2016) (0)
Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II) (2022) (0)
CEG_A_329424 441..449 (2021) (0)
Modulation of the Non-Canonical NFKB Pathways may Underlie Alternative Activation of Circulating CD14HI Monocytes in Hyper-Acute Liver Failure (2016) (0)
Sarcopenia is not associated with poor outcomes after transjugular intrahepatic portosystemic shunt insertion for refractory ascites (2020) (0)
Hyperammonaemia defines the risk of acute-on-chronic liver failure in clinically stable outpatients with cirrhosis (2022) (0)
Acute liver failure and the brain: a look through the crystal ball (2012) (0)
It is justified to biopsy presumed hepatocellular carcinoma (HCC) when the alfa fetoprotein (AFP) is normal. (2001) (0)
A SIGNIFICANT REDUCTION IN 'PRO-INFLAMMATORY' CD14LO/CD16HI MONOCYTES IN ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE: ASSOCIATION WITH OUTCOME AND CCR2 EXPRESSION (2010) (0)
Worsening of cerebral hyperaemia in acute liver failure (ALF) with terlipressin (2003) (0)
P27 Neutrophil dysfunction: the missing link between ammonia, infection and hepatic encephalopathy? (2010) (0)
Treatment of hepatic encephalopathy (2005) (0)
List of contributors (1998) (0)
519 CELLULAR TH1 AND TH2 IMMUNE RESPONSES TO ALCOHOL DEHYDROGENASE WITHIN THE LIVER OF PATIENTS WITH ALCOHOL-RELATED CIRRHOSIS DESPITE ABSTINENCE (2013) (0)
499 INTENSITY OF CELLULAR IMMUNE RESPONSES TO ALCOHOL DEHYDROGENASE IS ASSOCIATED WITH ALCOHOL CONSUMPTION IN PATIENTS WITH ALCOHOLIC LIVER DISEASE (2011) (0)
OP22 A significant reduction in “pro-inflammatory” CD14lo/CD16hi monocytes in paracetamol-induced acute liver failure: association with outcome and CCR2 expression (2010) (0)
Inflammation significantly exacerbates the effect of hyperammonemia on neurological function in chronic liver disease. (2002) (0)
Ammonia, infection and inflammation in hepatic encephalopathy. (2007) (0)
Alpha1-antitrypsin deficiency [4] (2009) (0)
P0168 : The impact on hospital resource utilisation of Rifaximin-alpha for hepatic encephalopathy in routine clinical practice: Real world data from seven UK liver centres (2015) (0)
Altered gut microbial profile is a proponent of bacterial translocation in acute-on-chronic liver failure (2016) (0)
Hepatic encephalopathy (2019) (0)
665 MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS), RATHER THAN THE NEED FOR RENAL REPLACEMENT THERAPY PER SE, DICTATES POOR PROGNOSIS IN PATIENTS WITH CIRRHOSIS ADMITTED TO ICU (2012) (0)
Ex-vivo Treatment of Neutrophils with a p38-MAPK Agonist in Patients with Acute and Chronic Liver Failure and Elevated Arterial Ammonia Improves Their Bacteriocidal Capacity (2011) (0)
99 FUNCTIONAL DEFECTS IN CIRCULATING MONOCYTES MAY CONTRIBUTE TO INCREASED SUSCEPTIBILTY TO INFECTION IN ALCOHOLIC HEPATITIS (2012) (0)
541 IMPAIRED NEUTROPHIL PHAGOCYTIC CAPACITY IN PATIENTS WITH ADVANCED CIRRHOSIS IS RELATED TO THE DEVELOPMENT OF AMMONIA-INDUCED NEUTROPHIL SWELLING (2010) (0)
[212] BRAIN SWELLING AND COMA IN CIRRHOTIC RATS ADMINISTERED ENDOTOXIN IS ASSOCIATED WITH INCREASED PROTEIN NITROSATION (2007) (0)
1416 PLASMA PHOSHOLIPID PROFILING BY METABONOMICS: HIGHLY ACCURATE OUTCOME PREDICTION IN DECOMPENSATED CIRRHOSIS (2012) (0)
192 THE EXCESS MORTALITY ASSOCIATED WITH BETA-BLOCKER THERAPY IN PATIENTS WITH DIURETIC INTOLERANT ASCITES CAN BE EXPLAINED BY WORSENING NEUTROPHIL DYSFUNCTION (2011) (0)
500 AN INFLAMMATORY TH1 AND TH17 CYTOKINE PROFILE CHARACTERISES CELLULAR IMMUNE RESPONSES TO ALCOHOL DEHYDROGENASE IN PATIENTS WITH ALCOHOLIC LIVER DISEASE (2011) (0)
Specific alterations of the immune checkpoint secretome are linked with antibacterial immunity in alcohol-related liver disease (2020) (0)
P052 LOW VITAMIN D, LOW BONE DENSITY, AND FRAGILITY FRACTURES ARE COMMON AMONG UK LIVER TRANSPLANT RECIPIENTS (2022) (0)
PWE-275 Multiple organ dysfunction syndrome (MODS), rather than the need for renal replacement therapy per se, dictates poor prognosis in patients with cirrhosis admitted to ICU (2012) (0)
P305 BLOCKADE OF PD1/TIM3 RESTORES FAVOURABLE IFNγ/IL10 IMMUNE AXIS IN ALCOHOL-RELATED LIVER DISEASE (2014) (0)
547 DOWN-REGULATION OF TOLL-LIKE RECEPTOR-2 AND -4 IN CIRCULATING NEUTROPHILS IN RESPONSE TO SYSTEMIC OXIDATIVE STRESS MAY CONTRIBUTE TO INCREASED SUSCEPTIBILITY TO INFECTION IN ALCOHOLIC HEPATITIS (2013) (0)
552 CIRCULATING NEUTROPHIL GRANULE SUBSET RELEASE IN RESPONSE TO BACTERIAL STIMULUS IS AUGMENTED IN PATIENTS WITH ALCOHOL-RELATED LIVER DISEASE AND MAY CONTRIBUTE TO ORGAN BYSTANDER DAMAGE (2013) (0)
Improvement in Hepatic Encephalopathy with Rifaximin Is Associated with Distinct Changes in the Metagenomic Species in the Saliva and Stool Microbiome and a Reduction in Systemic Inflammation - Results of the Rifsys Randomized Controlled Trial. (2018) (0)
Increased neutrophil actin production and translocation of myeloperoxidase in patients with acetaminophen-induced acute liver failure may contribute to multiorgan failure (2014) (0)
P52 Neutrophil dysfunction: a potential biomarker of poor prognosis in acute liver failure? (2010) (0)
Personal View A dent in our sobriety (2009) (0)
PWE-041 Mannose binding lectin deficiency as a predictor of severity, disease progression and outcome following paracetamol-induced acute liver failure (2010) (0)
232 EXPANDED CD14HI/CD16+ MONOCYTES IN ACUTE LIVER INJURY (ALI): ANGELS OR DEMONS? (2012) (0)
CD86 EXPRESSION BY CD14H1MONOCYTES IS A PROMISING NOVEL BIOMARKER FOR OUTCOME IN ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE (2010) (0)
Letter to the Editor - Reply to 'Ammonia - an old friend with a new area of application. (2022) (0)
Treatment of hepatic encephalopathy - Reply (2005) (0)
NEUTROPHIL DYSFUNCTION: A POTENTIAL BIOMARKER OF POOR PROGNOSIS IN ACUTE LIVER FAILURE? (2010) (0)
P: 46 Ammonia Is an Independent Biomarker of Poor Outcomes in Patients With Advanced Cirrhosis on the Transplant Waiting List (2019) (0)
193 Aseptic inflammation independent of its source is important in the development of advanced grades of encephalopathy in alcoholic cirrhosis (2004) (0)
Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial) (2018) (0)
Clinical science workshop: targeting the gut-liver-brain axis (2015) (0)
1361 ALCOHOL-INDUCED LIVER TOXICITY IS ASSOCIATED WITH NEUTROPHIL DYSFUNCTION IN A NOVEL IN-VITRO MODEL OF ACUTE LIVER INJURY (2012) (0)
PTU-016a Functional defects in circulating monocytes may contribute to susceptibility to infection in alcoholic hepatitis (2012) (0)
Ammonia is an independent biomarker of poor outcomes in patients with advanced cirrhosis (2020) (0)
PWE-143 Abnormal Platelets And The Formation Of Activated Neutrophil-platelet Complexes Following Platelet Administration Induces Neutrophil Activation And Release Of Reactive Oxygen Species In Liver Cirrhosis (2014) (0)
P315 PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS PRESENT STRONG CELLULAR Th1 IMMUNE RESPONSES TO ALCOHOL DEHYDROGENASE (2014) (0)
Editorial: platelet transfusions in cirrhosis—do the risks outweigh the unclear benefits? Authors’ reply (2018) (0)
PTU-020 Rifaxamin is a highly efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy (HE) (2012) (0)
909 LOWER MONOCYTE HLA-DR AND CD86 BUT MAINTAINED HLA-DQ. AND HIGHER CD80 EXPRESSION IN PARACETAMOL-INDUCED-ACUTE-LIVER-FAILURE: A PHENOTYPIC SWITCH TO INHIBITORY ANTIGEN PRESENTATION (2011) (0)
PWE-290 Active alcohol consumption induces functional immune paresis but paradoxically promotes endotoxin tolerance in those with advanced alcohol-related cirrhosis (2012) (0)
P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS (2014) (0)
PTU-092 Plasma Angiopoietin 2, A Circulating Marker of Endothelial Cell Activation, Is Elevated in Acute Alcoholic Hepatitis (2016) (0)
Type III interferon lambda derangements are associated with susceptibility to infection in alcohol-related liver disease (2020) (0)
P: 38 Rifaximin Reduces the Incidence of Spontaneous Bacterial Peritonitis, Variceal Bleeding and All-cause Admissions in Patients on the Liver Transplant Waiting List (2019) (0)
Patients with alcoholic hepatitis present strong Th1 cellular immune responses to alcohol dehydrogenase related to impairment of the PD-1/PD-L1 pathway due to high circulating levels of soluble PD-1 (2020) (0)
Recent Findings in the Gut-Liver Axis and Associated Disease Therapy A of selected treatment-related (2022) (0)

This paper list is powered by the following services:

Other Resources About Debbie Shawcross

en.wikipedia.org

What Schools Are Affiliated With Debbie Shawcross?

Debbie Shawcross is affiliated with the following schools: